"); //-->
Drug Name DAYHIST TABLET FP ALLERHIST-1 1.34 MG TAB SM ALLERGY RELIEF 1.34 MG T TAVIST-1 1.34 MG TABLET CLEMASTINE FUM 2.68 MG TAB CIMETIDINE 300 MG 50 ML CIMETIDINE 150 MG ML VIAL CIMETIDINE 300 MG 5 ML LIQU CIMETIDINE 300 MG 5 ML SOLN ACID REDUCER 200 MG TABLET CIMETIDINE 200 MG TABLET CIMETIDINE 200 MG TABLET FP HEARTBURN RLF 200 MG TAB HEARTBURN RELIEF 200 MG TAB HEARTBURN RELIEF TABLET QC HEARTBURN 200 TABLET SUNMARK ACID REDUCER 200 MG TAGAMET HB 200 MG TABLET CIMETIDINE 300 MG TABLET CIMETIDINE 300MG TABLET TAGAMET 300 MG TABLET CIMETIDINE 400 MG TABLET TAGAMET 400 MG TABLET CIMETIDINE 800 MG TABLET TAGAMET 800 MG TABLET RANITIDINE 1, 000 MG 40 ML RANITIDINE HCL 25 MG ML VIA ZANTAC 25 MG ML VIAL RANITIDINE 150 MG 10 ML SYR ZANTAC 150 MG 10 ML SYRUP ZANTAC 15 MG ML SYRUP RANITIDINE 150 MG TABLET ZANTAC 150 MG TABLET RANITIDINE 300 MG TABLET ZANTAC 300 MG TABLET FAMOTIDINE 10 MG-ML VIAL FAMOTIDINE 10 MG ML VIAL FAMOTIDINE 200 MG 20 ML VIA FAMOTIDINE 20 MG 2 VIAL FAMOTIDINE 40 MG 4 VIAL FAMOTIDINE 500 MG 50 ML VIA PEPCID 10 MG ML VIAL PEPCID 40 MG 5 ORAL SUSP FAMOTIDINE 20 MG TABLET PEPCID 20 MG TABLET FAMOTIDINE 40 MG TABLET PEPCID 40 MG TABLET AXID 150 MG PULVULE NIZATIDINE 150 MG CAPSULE AXID 300 MG PULVULE NIZATIDINE 300 MG CAPSULE AZATHIOPRINE SOD 100 MG VIA AZATHIOPRINE 50 MG TABLET IMURAN 50 MG TABLET CYCLOSPORINE 50 MG ML AMP SANDIMMUNE 50 MG ML AMPUL CYCLOSPORINE 100 MG ML SOLN SANDIMMUNE 100 MG ML SOLN INTAL INHALER CROMOLYN NEBULIZER SOLUTION INTAL NEBULIZER SOLUTION CROMOLYN SODIUM NASAL SPRAY SMAC PA Required 0.2845 Covered for duals yes yes yes yes no no no yes no yes yes yes yes yes yes yes no no no yes FP Generic Sequence Nbr 11655.
FDA Patent Exclusivity Drug Chemical Approval Expiration Expiration Nimotop Nimopidine N A N Nitro-Dur Nitroglycerin 1995 2010 None Nivadil Nilvadipine Not Approved Nolvadex Tamoxifen Citrate 1982-1994 2002-2003 None Nootropil Piracetam Not Approved Norvasc Amlodipine 1992 2006-2007 None Novantrone Mitoxantrone 1987 2005-2006 2003-2007 Nutropin Protropin Somatropin Somatrem 1993-2002 None 2003 Omnicef Cefdinir 1997 None None L-Asparaginase + Adenosine Deaminase Oncaspar + Adagen Ontak Denileukin Diftitox N A N Oxis Formoterol 1988-1992 None None Pantozol Pantoprazole 2000-2001 2005 2004-2005 Paraplatin Carboplatin 1989 2004 None Pediatric Combo Vaccines N A N Pentasa Mesalamine 1993 2002 None Pepcid Famotidine 1986-1994 None None Pergonal Menotropin 1982 None None Pharmorubicin Ellence Epirubicin Hydrochloride 1999 None 2006 Plavix Clopidogrel 1997 2003-2019 2002-2005 Plavix Iscover Clopidogrel 1997 2003-2019 2002-2005 Plendil Felodipine 1991-1994 2007 None Pletal Cilostazol 1999 None 2004 Polio Vaccine N A N Pravachol Pravastatin 1991-2001 2005-2014 2003-2005 Premarin Medroxyprogesterone Acetate 1982-1984 2012 None Prevacid Zoton Lansoprazole 1995-2002 2005-2010 2002-2005 Prevnar Pneumococcal 7-valent Vaccine None None None Primaxin Imipenem + Cilastatin 1985-1990 None None Prinivil Prinizide Lisinopril 1987 2002 None Proamatine Midodrine Hydrochloride 1996-2002 None 2003 Procardia Nifedipine 1982-1989 2003 None Procleix N A N Profasi Chorionic Gonadotropin Hormone N A N Prograf Tacrolimus 1994-1998 None None Prolastin Alpha-1 Proteinase Inhibitor N A N Proleukin Aldesleukin N A N Propecia Finasteride 1997 2006-2013 None Proscar Finasteride 1992 2006-2018 None Protonix Protium Pantoprazole 2000-2001 2005 2004-2005 Protopic Tacrolimus 2000 None None Proventil Albuterol 1982-1987 None None Provigil Modafinil 1998 2007-2014 2003-2005 Prozac Fluoxetine 1987-2001 2003-2008 2003-2005 Pulmicort Budesonide 1997-2000 2002-2007 2003 Pulmozyme Dornase Alfa N A N Pulmozyme Dornase Alfa N A N Puregon Follitropin Beta N A N Querto Carvedilol 1995-1997 2007-2016 2004 Rapamune Sirolimus 1999-2000 None None Rebif Interferon Beta-1A N A N A Refacto Recombinant Factor XIII N A N Relafren Nabumetone 1991 2002-2003 None Relpax Eletriptan Hydrobromide 2002 2013 2007 Remeron Mirtazapine 1996-2001 2010-2017 2005 Remicade Infliximab N A N Remicade Infliximab N A N Renagel Sevelamer Hydrochloride 1998-2000 2013-2014 2003 Reopro Abciximab N A N Requip Ropinirole 1997-1999 2007 None Isopropyl Unoprostone 2000 2008-2011 2005 Rescula Major Drug Database. Updates available at : geocities pchang 99 drugdatabase.
ESTRADERM . 13, 50 estradiol . 12, 13, 50 ESTRASORB . 50 ESTRING . 50 ESTROGEL . 50 estropipate . 12, 50 ESTROSTEP FE . 48 ethambutol . 23 ethinyl estradiol levonorgestrel. 12 ETHMOZINE . 30 ethosuximide . 36 etodolac . 15 etodolac ext-rel. 15 etoposide . 27 EULEXIN . 25 EURAX. 72 EVISTA . 13, 52 EVOXAC. 57 EXELON . 37 EXJADE . 59 EXUBERA . 45 FACTIVE . 20 famotidine . 55 FAMVIR . 24 FARESTON . 25 FASLODEX . 25 FAZACLO . 39 FELDENE. 15 felodipine ext-rel. 32 FEMARA. 25 FEMCON FE . 48 FEMHRT. 50 FEMRING . 50 FEMTRACE . 50 fenofibrate . 10 fenofibrate, micronized . 30 fenoprofen . 15 fentanyl citrate oral transmucosal . 17 fentanyl transdermal. 17 FENTORA . 17 FERTINEX . 51 fexofenadine . 13, 63 FINACEA . 71 finasteride . 13, 57 FIORICET. 17, 18 FIORINAL. 17, 18 FLAGYL. 24 FLAGYL 375 MG . 24 FLAGYL ER . 58 flecainide . 29 FLEXERIL . 42 FLOLAN . 35 FLOMAX. 13, 57 FLONASE . 66 85.
This segment of the emedtv library takes a detailed look at methods used to lower cholesterol, including lifestyle changes, medications, or a combination of both, for example, famotidine allergy.
This fall the federal all party MP Standing Committee on Health was in Winnipeg. The Standing Committee is studying prescriptions drugs regarding rising costs, mechanisms for reviewing and controlling prices, monitoring of adverse effects and prescribing practices, marketing to and lobbying of prescribers and dispensers, direct to consumer advertising, and misuse, abuse and addiction with the general populations, as well as other related issues. The Registrar made a presentation to the Standing Committee and copies of the brief are available through the office.
T's clear that there is a spirit of joy and celebration here that is affirming for all of us, " said Brian McCagh, vice president of Oncology Services, as he began the ceremonies for Cancer Survivors Day in June. Lawrence Lessin, MD, medical director, Washington Cancer Institute, noted that the crowd of more than 300 included a total of 1, 050 years of cancer survivorship. "There are 10, 000 of us cancer survivors in the United States today, " said Lessin, himself a cancer survivor, "and 75 percent of those diagnosed today will be alive five years from now." Keynote speaker Aisha Karimah, NBC4's director of community affairs, spoke of her own cancer survivorship. "What's faith got to do with it? Everything. Faith is the substance of things hopeful." Karimah thanked her physicians, Francisco King, Arthur West, Mark and fexofenadine.
Many of the patients seen by physical therapists have primaly or secondaly diagnosesfor which cardiovascular- orpulmonaly-active medications may be prescribed. n e r need, therefore, forphysical therapists to understand the phamacologic treatment of such patients. n i s article discusses medications commonly used in the treatment of pulmonaly ciisorders. These medications are t ically divided into the following categories: bronchodilators, antiinflammatoly agents, decongestants, antihistamines, antitussiues, mucokinetics, respiratoly stimulants and depressants, and paralyzing and antimicrobial agents. Regardless of which group a particular medication belongs to, the rationale for its prescription centers on promoting bronchodilation or relieving bronchoconstriction, facilitating the removal of secretions from the lungs, improving alveolar ventilation or oxygenation, or optimizing the breathing pattern, The relative importance of each of these goals depends on the specijc disease process involved and the resultant respiratory pmblemCs ; . [Cahalin LP, Sadowsky HS. Pulmonaly medications. Phys mer. 1995; 75: 397- The prescription of any pulmonaly medication is founded on four basic goals: 1 ; promotion of bronchodilation or relief of bronchoconstriction, 2 ; facilitation of the removal of secretions from the lungs, 3 ; improvement of alveolar ventilation or oxygenation, and 4 ; optimization of the breathing The relative importance of each of these goals depends on the specific disease process and the resultant respiratory problem s ; . Consequently, pulmonaly-active medications are typically grouped in accordance with their principal desired effect: bronchodilators, anti-inflammatory agents, decongestants, antihistamines, antitussives, mucokinetics, respiratory stimulants and depressants, and paralyzing and antimicrobial agents. Each.
ESTRACE CREAM. 31 estradiol tablet 30 estradiol patch . 30 estradiol tds. 31 ESTRING VAGINAL RING . 31 estropipate tab 31 ESTROSTEP FE28 TABLET. 31 ethambutol . 14 ethosuximide. 11 ETHYOL . 15 etidronate disodium . 30 etodolac . 7, 13 etoposide 20 mg ml vial . 15 EVISTA. 30, 32 EXELON. 11 EXJADE. 41 F FABRAZYME. 27 famotidine. 28 FAMVIR 125 MG TABLET . 17 FASLODEX SYRNGE . 32 FELBATOL. 11 felodipine er . 22 FEMARA . 15 FEMHRT TABLET . 31 FEMRING VAGINAL RING . 31 FEMTRACE TABLET . 31 fenofibrate . 23 fenoprofen . 8, 13 fentanyl . 7 fexofenadine . 37 FIRST 2% TESTOSTERO NE OINT . 31 FIRSTTESTOSTERO NE MC 2% CR FLAGYL ER . 10 FLAREX 0.1% EYE DROPS36 flecainide acetate . 21 FLOMAX. 29 FLOVENT HFA 38 FLOXIN 0.3% EAR DROPS37 and pseudoephedrine.
68. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage Coca-Cola ; on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235-7. Fumagalli I, Klein M, Fischer R. Comparison of intravenous with oral pantoprazole in symptom relief and healing of reflux esophagitis. Gastroenterology 1998; 114: A126. Abst ; 70. Plein K, Schneider A, Fischer R, Hotz J. [Efficacy and safety of sequential intravenous and oral treatment of pantoprazole in reflux esophagitis]. Leber Magen Darm 2000; 30: 164-8. Wurzer H, Schutze K, Bethke T, Fischer R, Luhmann R, Riesenhuber C. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology 1999; 46: 1809-15. Paul J, Metz D, Maton P, Pisegna J, Pratha V, Martin P. Pantoprazole IV treatment decreases antacid usage in patients with gastroesophageal reflux disease. Gastroenterology 1999; 116: A283. Abst ; 73. Panos MZ, Walt RP. Current management of bleeding peptic ulcer. A review. Drugs 1993; 46: 269-80. Gilbert DA. Epidemiology of upper gastrointestinal bleeding. Gastrointest Endosc 1990; 36: 8-13. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992; 304: 143-7. Katschinski B, Logan R, Davies J, Faulkner G, Pearson J, Langman M. Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci 1994; 39: 706-12. Vreeburg EM, Ramnath A, Snel P, et al. Follow-up of bleeding gastroduodenal ulcers. Gastroenterology 1996; 110: A288. Abst ; 78. Hochain P, Capet C, Merle V, Michel P, Riachi G, Ducrottea P. Bleeding peptic ulcer BPU ; in patients aged over 80 years: incidence and prognosis. Gut 1995; 37 Suppl 2 ; : A47. Abst ; 79. Saltzman JR, Zawacki JK. Therapy for bleeding peptic ulcers. N Engl J Med 1997; 336: 1091-3. Fullarton GM, Macdonald AM, Mann SG, McColl KE. Controlled study of the effects of intravenous famotidine on intragastric pH in bleeding peptic ulcers. Aliment Pharmacol Ther 1991; 5: 77-84. Green FW, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38-43. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut 1989; 30: 1704-7. Collen MJ, Kalloo AN, Sheridan MJ. Bleeding duodenal ulcer. Role of gastric acid hypersecretion. Dig Dis Sci 1993; 38: 269-75. Collins R, Langman M. Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985; 313: 660-6. Walt RP, Cottrell J, Mann SG, Freemantle NP, Langman MJ. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340: 1058-62. Brunner G, Luna P, Thiesemann C. Drugs for pH control in upper gastrointestinal bleeding. Aliment Pharmacol Ther 1995; 9 Suppl 1 ; : 47-50. 87. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4. Kiilerich S, Rannem T, Elsborg L. Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer. Digestion 1995; 56: 25-30. Brunner G, Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. Digestion 1990; 45: 217-25. Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Borsch G. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997; 40: 36-41. Sanders SW, Buchi KN, Moore JG, Bishop AL. Pharmacodynamics of intravenous ranitidine after bolus and continuous infusion in patients with healed duodenal ulcers. Clin Pharmacol Ther 1989; 46: 545-51. Lanas A, Artal A, Blas JM, Arroyo MT, Lopez-Zaborras J, Sainz R and galantamine.
Famotidine canadaHumoral immunity. The detection of autoantibodies directed against various ovarian targets strongly supports the hypothesis of an autoimmune aetiology of POF. The rst reports on such antibodies included mainly patients with POF and an associated adrenal autoimmune disease. These patients had antibodies that recognized several types of steroid-producing cells of the adrenal cortex, testis, placenta and ovary and were therefore called steroid cell antibodies SCA ; Irvine et al., 1968; Sotsiou et al., 1980 ; . The prevalence of SCA depends on the clinical features: they can be detected in ~60% of APS-I patients and 2540% of APS-II patients Hoek et al., 1997 ; , but the highest prevalence, i.e. 78 100%, has been shown in patients with both Addison's disease and POF Sotsiou et al., 1980; Betterle et al., 1993 ; . In a long-term study, it has been shown that 3343% of normally cycling women with polyendocrinopathy and SCA would develop ovarian failure within 815 years Ahonen et al., 1987; Betterle et al., 1993 ; . The presence of these antibodies is thus a risk factor for POF. In patients whose POF is associated with autoimmune pathologies other than Addison's disease Betterle et al., 1993; Falorni et al., 2002; Dal Pra et al., 2003 ; , as well as in isolated POF De Moraes-Ruehsen et al., 1972; Betterle et al., 1993; Falorni et al., 2002; Dal Pra et al., 2003 ; , the prevalence of SCA remains 10%. Many other antiovarian antibodies have been detected in these cases and numerous publications have dealt with this subject over the last 30 years. Despite this considerable scientic work, the detection of antiovarian antibodies still produces conicting results and until now, neither the specicity nor the diagnostic signicance of these antibodies has been unanimously established, for example, famotidine feline.Departments of Environmental Health Sciences [S. N. K.] and Epidemiology [S. L. R. K.], University of Michigan School of Public Health, Ann Arbor, Michigan 48109, and Departments of Biostatistics and Epidemiology [A. H. W., T. R. R.] and Urology [A. J. W., S. B. M.], and the Cancer Center [A. J. W., S. B. M., T. R. R.], University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021 and glibenclamide. Famotidine dosing the famotidine dose for treating gerd in adults is 20 mg twice daily. | Famotidine no prescriptionPrusik M., Lewczuk B., Bulc M., Przybylska-Gornowicz B. Division of Histology, Department of Functional Morphology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Olsztyn, Poland mprusik gmail Aims: The avian pineal is directly photosensitive due to the presence of photopigments, among which pinopsin seems to be one of the most important and responsible for acute influence of light on the pinealocyte activity. Up till now, pinopsin has been detected in the chicken and the Japanese quail. The purpose of our study was to check the presence and distribution of pinopsin in the pineals of domestic turkeys at various stages of postembryonic life and as in cultured pinealocytes. Methods: Pineals of 1-day-, 2-, 14-, and 56-week-old turkeys as well as monolayer cultures of turkey pineal cells were fixed and subjected to immunohistochemical staining with primary antibody against pinopsin. Results: The pinopsinimmunoreactivity was observed in apical processes of rudimentaryreceptor pinealocytes limiting the follicular lumen and in short processes originating from secretory pinealocytes laying in outer layer of the follicular wall in the pineals of turkeys from 1 day to 1 year old. The number of secretory pinealocytes with pinopsin-positive processes increased with age. In monolayer cultures, the positive staining for pinopsin was observed in pinealocytes. It was especially prominent in short cytoplasmic processes originating from cytoplasmic pools of cells. Conclusions: Pinopsin is present in turkey pineal glands during the whole period of postembryonic life and shows very specific distribution and glucovance. A b c healthy information » canadian pharmacy drug » canadian discount pharmacy on allergies » canadian internet pharmacy on asthma » canadian online pharmacy on diabetes » cheap online pharmacy on depression » discount online pharmacy on heart disease » drug online pharmacy on breast cancer » online pharmacy on hepatitis c » online pharmacy prescription for parkinson's » licensed online pharmacy on menopause » discount pharmacy on acne » internet pharmacy on athlete's foot » international pharmacy on chickenpox » online discount pharmacy on cold sores » canadian pharmacy online on diarrhea » online drug store on eczema » canadian drug store on glaucoma » internet drug store on high blood pressure » canadian online drug store on impotence » best online pharmacy tips » canada online pharmacy as a cost cutter » canadian discount online pharmacy info » discount drug information » generic drug info » discount drug prescription info » canada pharmacy precautions » osteoporosis » osteoporosis treatment » osteoporosis causes » osteoporosis symptoms » osteoporosis prevention buy elavil online - buy elavil antidepressant prescription drug info abilify accolate accupril accuretic aciphex actonel actos acular advair agenerase aggrenox 200 25 aldara alesse allegra alphagan altace amaryl amerge ansaid anthelios arava aricept arimidex atrovent avandamet avandia avapro azopt baclofen benoxyl betagan betaxolol boniva bumex buspar cafergot calcitonin - captopril cardizem cardura casodex celebrex celexa cellcept cialis cimetidine cipralex cipro claritin climara combivent coreg cosopt cotazym coumadin cozaar crestor cymbalta danazol daypro depen detrol diovan doxepin edecrin - effexor elavil elmiron eltroxin epivir etidronate evista exelon famotidine famvir feldene femara femhrt fenofibrate flexeril flomax flonase florinef flovent floxin fluoride folic acid forteo fosamax gabapentin geodon gleevec glyburide gonal f halog herplex humatin hydralazine hydrea hydrodiuril hytrin hyzaar imdur imipramine imitrex isoptin k-dur 1500mg keppra ketorolac kytril labetalol lamictal lamisil lanoxin lasix lescol levitra levsin lipitor lopid lotensin lumigan 03% macrobid maxalt metformin metoprolol mevacor minocin mirapex namenda naproxen nasacort nexium niaspan norvasc oxytrol paroxetine pentasa permax plaquenil plavix plendil prazosin pravastatin pravochol premarin premplus prevacid prinivil procan propecia propranolol protonix prozac questran quibron qvar relafen remeron reminyl renagel requip rexall rifadin rythmol septra singulair spiriva 18mcg sustiva synthroid synvisc tambocor tazorac tenormin topamax tricor ultravate valtrex vasotec viagra wellbutrin xenical yohimbine zerit zestril zetia zocor zofran zoloft zyloprim zyprexa generic name: amitriptyline a mee trip ti leen ; brand names: elavil, endep, vanatrip elavil: important information: it may be 4 weeks or more before you start to feel better, but do not stop taking elavil without first talking to your doctor.
Generic Name Maximum Daily Dosage Maximum Daily Drug Class Standards Ages 18 to Dosage Standards 65 Over Age 65 Benazepril 80mg ACE Inhibitor Captopril 450mg ACE Inhibitor Enalapril 40mg ACE Inhibitor Fosinopril 80mg ACE Inhibitor Lisinopril 40mg ACE Inhibitor Quinapril 40mg ACE Inhibitor Ramipril 20mg ACE Inhibitor Acebutolol 1200mg 800mg beta-blocker Atenolol 200mg beta-blocker Betaxolol 20mg beta-blocker Bisoprolol 20mg beta-blocker Labetalol 2400mg beta-blocker Metoprolol 450mg beta-blocker Metoprolol XR 400mg beta-blocker Nadolol 320mg beta-blocker Pindolol 60mg beta-blocker Propanolol 640mg beta-blocker Propranol SR 640mg beta-blocker Sotalol 640mg beta-blocker Timolol 120mg beta-blocker Amlodipine 10mg calcium channel blocker Diltiazem 480mg calcium channel blocker Diltiazem CD 480mg calcium channel blocker Diltiazem SR 360mg calcium channel blocker Diltiazem XR 540mg calcium channel blocker Felodipine 10mg calcium channel blocker Isradipine 20mg calcium channel blocker Nicardipine 120mg calcium channel blocker Nifedipine 180mg calcium channel blocker Nifedipine CC 120mg calcium channel blocker Nifedipine XL 120mg calcium channel blocker Verapamil 720mg calcium channel blocker Verapamil HS 540mg calcium channel blocker Verapamil SR 480mg calcium channel blocker Digitoxin 0.1mg Cardiotonic Digoxin 0.5mg Cardiotonic Atorvastatin 80mg HMG CoA RI Cerivastatin 0.8mg HMG CoA RI Fluvastatin 80mg HMG CoA RI Lovastatin 80mg HMG CoA RI Pravastatin 40mg HMG CoA RI Simvastatin 80mg HMG CoA RI Effective Date 5 15 2000 Generic Name Amobarbital and Secobarbital Butabarbital Chloral Hydrate Estazolam Ethchlorvynal Flurazepam Pentobarbital Quazepam Secobarbital Temazepam Triazolam Zolpidem Alprazolam Chlordiazepoxide Clonazepam Clorazepate Diazepam Diazepam SR Halazepam Lorazepam Oxazepam Cisapride Metoclopramide Misoprostol Sucralfate Cimetidine Famotidine Nizatidine Ranitidine Celecoxib Choline Mg Sulfate Diclofenac Diclofenac Potassium Diclofenac XR Diflunsil Etodolac Etodolac XL Fenoprofen Flurbiprofen Maximum Daily Maximum Daily Drug Class Dosage Standards Dosage Standards Ages 18 to 65 Over Age 65 200mg sedative-hypnotic 120mg 2000mg 2mg sedative-hypnotic 2000mg sedative-hypnotic 2mg sedative-hypnotic 1000mg sedative-hypnotic 15mg sedative-hypnotic 200mg sedative-hypnotic 15mg sedative-hypnotic 200mg sedative-hypnotic 15mg sedative-hypnotic 0.25mg sedative-hypnotic 10mg sedative-hypnotic 0.375mg Anxiolytic 300mg Anxiolytic 20mg Anxiolytic 90mg Anxiolytic 30mg Anxiolytic 30mg Anxiolytic 40mg Anxiolytic 10mg Anxiolytic 60mg Anxiolytic 80mg Gastrointestinal agent 40mg Gastrointestinal agent 800mcg Gastrointestinal agent 4gm Gastrointestinal agent 900mg H2 antagonist 640mg H2 antagonist 300mg H2 antagonist 300mg H2 antagonist 400mg NSAID 7.2gm NSAID 200mg NSAID 200mg NSAID 225mg NSAID 1.5gm NSAID 1200mg NSAID 1200mg NSAID 3200mg NSAID 300mg NSAID Effective Date 5 30 2000 TABLE 8 Therapy Duration Standards Recommended by the DURB 4 25 01 Brand Name Generic Name Age Daily Days Dosage Duration Restoril 15mg cap Restoril 30mg cap Restoril 7.5mg cap Halcion 0.125mg tab Halcion 0.25mg tab Halcion 0.5mg tab Zyban 150mg SA tab Toradol 10mg tab Sporanox 10mg ml soln Sporanox 150mg cap Temazepam Temazepam Temazepam Triazolam Triazolam Triazolam Bupropion Ketoralac Itraconazole Itraconazole 65 to 999 65 to 999 65 to 999 65 to 999 65 to 999 65 to 999 18 to 999 18 to 999 65 to 999 65 to 999 0.53 .26 TABLE 9 APAP containing Narcotics Recommended by the DURB for Therapeutic Duplication Standards 4 25 01 GCN Drug Name Strength 12486 Norco 5-325mg 50756 Percocet 7.5-500mg 50766 Percocet 10-650mg 55401 Tlyenol W Codeine 12-120mg 5ml 70103 Phenaphen W Codeine 30-325mg 70105 Phenaphen W Codeine 60-325mg 70110 Capital W Codeine 12-120mg 5ml 70131 Tylenol #2 15-300mg 70134 Tylenol #3 30-300mg 70136 Tylenol #4 60-300mg 70140 Fioricet W Codeine 30mg 70320 Hydrocet, Lorcet HD 5-500mg 70330 Hydrocodone Acetaminophen, Norco 10-325mg 70331 Hydrocodone APAP, Anexsia, Lortab, 5-500mg Vicodin 70332 Hydrocodone APAP, Lorcet 10 650, 10-650mg Hydrocodone APAP, Anexsia, Lorcet 7.5-650mg Plus 70334 Hydrocodone Acetaminophen, Lortab 10-500mg 70335 Hydrocodone APAP, Vicodin ES 7.5-750mg 70338 Hydrocodone APAP, Lortab 2.5-500mg 70339 Hydrocodone APAP, Lortab 7.5-500mg 70361 Hydrocodone W Acetaminophen, Lortab 2.5-167 5ml 70363 Hydrocodone W Acetaminophen, Vicodin 10-660mg HP 70401 Zydone 5-400mg 70402 Zydone 7.5-400mg 70403 Zydone 10-400mg 70470 Roxicet 5-325mg 15ml 70490 Roxicet 5-500mg 70491 Oxycodone W Acetaminophen, Percocet, 5-325mg Endocet, Roxicet 70492 Percocet 2.5-325mg 70500 Oxycodone W Acetaminophen, Roxilox, 5-500mg Tylox 70925 Propoxyphene Hcl W APAP, Wygesic 65-650mg 70931 Propox Napsylate APAP, Darvocet N 100 100-650mg 70931 Propoxyphene Napsylate W AP 100-650mg 70933 Darvocet-N 50 50-325mg 71050 Pentazocine Acetaminophen, Talacen 25-650mg 85319 Maxidone 10-750mg 13909 Ultracet 37.5-325mg and inderal and famotidine. |
While triptans are generally effective in cluster headache , extreme caution is advised, because of the temptation to overuse this drug, and also the tendency for cluster to occur in persons with higher risks of heart attack.
Selected otc medications for intermittent heartburn otc medication brand name active ingredient s ; antacids famotidine, 10 mg, plus 800 mg of caco 3 and 165 mg of mg oh ; 2 abbreviations: al oh ; 3 , aluminum hydroxide; caco 3 , calcium carbonate; h2ra, histamine-2 receptor antagonist; mg oh ; 2 , magnesium hydroxide; otc, over the counter; ppi, proton pump inhibitor.
Medicines which lose their reimbursement status are Lanzo lansoprazole ; , Pariet rabeprazole ; , Losec and Losec Mups, Losec Medartuum, all H2 antagonists, Andapsin sucralfate ; , Gaviscon alginic acid ; and novaluzid aluminium, magnesium ; . A number of companies have however appealed the LFn's decision regarding discontinued reimbursement. Therefore a number of medicines, despite the LFn's decision, may retain their reimbursement status until the courts have ruled on the matter. This is the case for Lanzo, Losec Medartuum, Andapsin as well as the H2 antagonists Acinil cimetidine ; , Famotidin Hexal famotidine ; , Artonil ranitidine ; , Inside Brus ranitidine ; , Ranitidin Hexal, Ranitidine Merck nM, Ranitidin Recip and Ranitidin Sandoz. Decisions release 175 million Swedish crowns Continuing to reimburse generic omeprazole, while not reimbursing other equal but more expensive medicines, means that patients receive the same effects from treatment at a cost that may be approximately 175 million crowns lower. The money released through this may be used for new innovative treatment methods or for other areas of urgent need within the healthcare sector. The decisions enter into force, unless appealed, from the 1st of May, 2006. Following this the medicines which have been removed from the benefits scheme are not reimbursed. If the decisions regarding one or more medicines are appealed by the companies in question, then the relevant medicines will continue to be reimbursed until the case has been resolved in court. Sales of almost 900 million crowns The medicines in the group had a turnover of almost 900 million Swedish crowns within the pharmaceutical benefits scheme. This answers for almost four percent of the total sales within the benefits system. Sales in terms of both crowns and volume have increased steadily over the past 30 years. This is mainly due to the introduction of new pharmaceuticals. In 1978 sales in the group were 86 million crowns. The major part of this consisted of medicines which neutralised hydrochloric acid. Since then both H2 antagonists and proton pump inhibitors have been introduced. Sales value increased steadily up till roughly a year ago when Losec omeprazole ; lost its patent and generic omeprazole entered the market at a considerably lower price. Sales in crowns decreased then somewhat, while the actual sales volume continued to increase.
© 2007